About FDA
Number of Best Pharmaceuticals for Children Act (BPCA) reviews completed in the month
Dictionary:
These measures has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 1 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 0 |
| Jan 2011 | N/A | 0 |
| Feb 2011 | N/A | 0 |
| Mar 2011 | N/A | 0 |
| Apr 2011 | N/A | 0 |
| May 2011 | N/A | 0 |
| Jun 2011 | N/A | 0 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 0 |
| Sep 2011 | N/A | 0 |
FY 2011 Total: 1
Number of Pediatric Research Equity Act (PREA) reviews completed in the month
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 3 |
| Nov 2010 | N/A | 2 |
| Dec 2010 | N/A | 1 |
| Jan 2011 | N/A | 0 |
| Feb 2011 | N/A | 0 |
| Mar 2011 | N/A | 0 |
| Apr 2011 | N/A | 0 |
| May 2011 | N/A | 3 |
| Jun 2011 | N/A | 0 |
| Jul 2011 | N/A | 3 |
| Aug 2011 | N/A | 0 |
| Sep 2011 | N/A | 6 |
FY 2011 Total: 18
Number of combined BPCA/PREA safety reviews completed in the month
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 0 |
| Nov 2010 | N/A | 1 |
| Dec 2010 | N/A | 1 |
| Jan 2011 | N/A | 0 |
| Feb 2011 | N/A | 0 |
| Mar 2011 | N/A | 0 |
| Apr 2011 | N/A | 0 |
| May 2011 | N/A | 0 |
| Jun 2011 | N/A | 2 |
| Jul 2011 | N/A | 3 |
| Aug 2011 | N/A | 0 |
| Sep 2011 | N/A | 0 |
FY 2011 Total: 7
Number of safety reviews completed under the Pediatric Rule
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 0 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 0 |
| Jan 2011 | N/A | 0 |
| Feb 2011 | N/A | 0 |
| Mar 2011 | N/A | 0 |
| Apr 2011 | N/A | 0 |
| May 2011 | N/A | 0 |
| Jun 2011 | N/A | 0 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 0 |
| Sep 2011 | N/A | 0 |
FY 2011 Total: 0
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
